Originally Aired: November 18, 2021
Time: 8:00 am PT, 11:00 am ET, 17:00 CET
Cell therapy development programs generate encouraging pre-clinical and clinical results with the promise that these tailored therapeutics can provide a curative rather than maintenance therapy. Therapies are being developed across the spectrum from academic institutions to small and medium biotechs/biopharma as well as large pharma companies which have all invested significantly in the cell and gene therapy (CGT) field. As additional CGT therapies gain approval, specifically in solid tumors and auto-immunity, the addressable patient populations will grow requiring scaled -out/-up commercial manufacturing. Although the CGT field is experiencing significant tailwinds, challenges remain. Cell sourcing has long been considered a pain-point which is potentially compounded with the necessity to develop robust GMP manufacturing processes and appropriate analytical methods.
In this GEN webinar, Dr. Matthew Hewitt and Dr. Kimberly Negrin—experts in the field of human-derived biological products and manufacturing—will explore these distinct challenges and strategies to mitigate them. From the sheer volume of donors necessary to support cell therapy programs and the benefit of dedicated donor pools—to current testing and manufacturing gaps and the emerging solutions and processes that can increase quality, consistency, and efficiency.
A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelists.
Produced with support from: